Age-related macular degeneration (AMD ... As of 2023, the only FDA-approved treatments for dry AMD are two injectable drugs. These treatments are constrained by potential complications from ...

Since July 2024, faricimab has also been approved in Europe for the treatment of visual ... to develop compounds to treat dry age-related macular degeneration (AMD) and Stargardt disease - both ...

Breakthroughs in age-related macular degeneration (AMD) treatments have revolutionized the management of this progressive and potentially devastating eye disease. These include treatments such as ...

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced an affiliate has acquired Whitecap Biosciences, ...

The FDA has also granted a breakthrough therapy designation ... geographic atrophy (GA), an advanced stage of dry age-related macular degeneration (dAMD). Phase II expansion portion of the phase ...

This strategic move is aimed at bolstering Bausch + Lomb's clinical-stage pipeline with promising new treatments ... a form of advanced dry age-related macular degeneration, impacts around ...

Age-related macular degeneration (AMD ... The only FDA-approved treatments for dry AMD as of 2023 are two injectable drugs, which are limited by concerns over complications from intravitreal ...

Izervay (avacincaptad pegol) is a prescription injection used to treat severe age-related macular degeneration ... severe vision loss than dry AMD. During Izervay treatment, your doctor will ...

Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and ...